TRANSGENOMIC INC (TBIO) is a publicly traded company in the Unknown sector. Across all available filings, 35 corporate insiders have executed 278 transactions totaling $3.0B, demonstrating a bullish sentiment with $2.5B in net insider flow. The most recent transaction on Jul 24, 2024 involved a transaction of 8,390 shares valued at $0.
No significant insider buying has been recorded for TBIO in the recent period.
No significant insider selling has been recorded for TBIO in the recent period.
Based on recent SEC filings, insider sentiment for TBIO is bullish with an Insider Alignment Score of 91/100 and a net flow of $2.5B. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at TRANSGENOMIC INC (TBIO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 35 insiders are actively trading TBIO stock, having executed 278 transactions in the past 90 days. The most active insider is Sanofi (Executive), who has made 2 transactions totaling $2.7B.
Get notified when executives and directors at TBIO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jul 24, 2024 | B. Weissman James | Executive | Award | 8,390 | $N/A | $0 | |
| Jul 24, 2024 | R. Hodges Michael | Executive | Award | 8,390 | $N/A | $0 | |
| Jul 24, 2024 | E. Hlavinka Sarah | Executive | Award | 8,390 | $N/A | $0 | |
| Jul 24, 2024 | J. Golub Steven | Executive | Award | 8,390 | $N/A | $0 | |
| Jul 24, 2024 | Krueger Todd | Executive | Award | 8,390 | $N/A | $0 | |
| May 1, 2024 | J. Herrema Gregory | Executive | Award | 31,486 | $N/A | $0 | |
| May 1, 2024 | K. Nachtsheim Jami | Executive | Award | 34,297 | $N/A | $0 | |
| May 1, 2024 | A. Tsingos Christine | Executive | Award | 37,109 | $N/A | $0 | |
| May 1, 2024 | Tumolo Annette | Executive | Award | 36,406 | $N/A | $0 | |
| May 1, 2024 | Witney Frank | Executive | Award | 48,354 | $N/A | $0 | |
| Apr 17, 2024 | Eugene Esser Eric | Executive | Award | 100,000 | $N/A | $0 | |
| Mar 1, 2024 | Cutler Rob | Executive | Payment | 1,376 | $0.53 | $729 | |
| Mar 1, 2024 | Glenn Gibson Daniel | Executive | Payment | 656 | $0.53 | $348 | |
| Mar 1, 2024 | Eugene Esser Eric | Executive | Payment | 3,340 | $0.53 | $1.8K | |
| Mar 1, 2024 | Robert Nelson Todd | Executive | Payment | 4,756 | $0.53 | $2.5K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 182 | $2.8B | 74.1% |
Other(J) | 2 | $685.7M | 18.4% |
Sale(S) | 33 | $273.0M | 7.3% |
Conversion(C) | 26 | $5.3M | 0.1% |
Exercise(M) | 6 | $566.8K | 0.0% |
Payment(F) | 7 | $10.3K | 0.0% |
Award(A) | 21 | $0 | 0.0% |
Gift(G) | 1 | $0 | 0.0% |
Insiders at TRANSGENOMIC INC are accumulating shares at an accelerated pace. With 35 insiders making 278 transactions totaling $2.8B in purchases versus $273.0M in sales, the net buying activity of $2.5B signals strong executive confidence. Sanofi (Executive) leads the buying activity with $2.7B in transactions across all time.